A new solution developed by IBM (NYSE: IBM), Novartis and Vodafone with the Roll Back Malaria Partnership, is helping to save lives using everyday technology to improve the availability of anti-malarial drugs in remote areas of Tanzania. Called “SMS for Life”, the initiative uses a combination of mobile phones, SMS…
Botox maker Allergan says a proposed tax on cosmetic surgeries and procedures– such as Botox injection –would have a small impact on the company, but it’s still actively fighting the measure. Report
Original Source of Allergan says ‘Botax’ wouldn’t hurt sales much
Pfizer fights back: The drugmaker issued a statement
Riddle me this: Why would children covered by Medicaid get antipsychotic drugs four times more often than children covered by private insurance? And why would the Medicaid kids often get those drugs for less severe conditions than their middle-class counterparts did? The New York Times poses these questions today…
GlaxoSmithKline has paid out almost $1 billion to settle lawsuits
Bristol-Myers Squibb is on the lookout for a new CFO. Jean-Marc Huet ( photo ), now EVP and chief financial officer, will leave the company at year’s end, to be replaced on an interim basis by Charles Bancroft, most recently VP of Finance for Bristol’s global biopharma business. Huet…
As usual when oncologists get together to talk shop, lots of pharma news hit the streets over the weekend during the annual Breast Cancer Symposium in San Antonio. Here’s a sampling of developments for already approved therapies: Nexavar , the Bayer/Onyx Pharmaceuticals drug, may trounce some cancers’ resistance to…
GlaxoSmithKline Biologicals SA (GSK) and Intercell announced an agreement to form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine for travellers’ diarrhoea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the…
EQT Partners AB, the last private-equity bidder for German generic-drug maker Ratiopharm GmbH, is seeking to team up with Actavis Group to bolster its chances of beating large pharmaceutical companies like Pfizer
An FDA reviewer has backed